Stablecoin Development Corporation · AMEX:SDEV
Stablecoin Development — NovaBay Pharmaceuticals — Investor Presentation (July 2024)
18 slides from Stablecoin Development's investor presentation, July 2024
Slide 1: Corporate Update
Corporate Update July 2024 NYSE American: NBY www.novabay.com www.avenova.com
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements, within the meaning of applicable U.S. securities laws, which statements can, in some cases, be identified with terms such as "anticipate," "believe," "could," "continue," "expect," "estimate," "intend," "may," "might,“
Slide 3: Corporate Overview - NBY is a commercial eyecare company
Corporate Overview - NBY is a commercial eyecare company COMPLETE DRY EYE PRODUCT PORTFOLIO AVENOVA® - BRANDED PORTFOLIO • Best-in-class Avenova products for each step of the • Suite of Rx and OTC products leverage the brand standard at home dry-eye treatment regimen. recognition of the Avenova lid
Slide 4: Investment Highlights
Investment Highlights Predictable, Recurring Revenue Multipronged Growth Strategy Expense Management Consumable personal healthcare As a purely commercial organization, DTC marketing efficiencies products with high customer loyalty R&D and clinical expenses are contributed to 12% YOY decrease in cre
Slide 5: Executing on Business Strategy - growing beyond Avenova
Executing on Business Strategy - growing beyond Avenova Q4 2023 Q4 2023 Q1 2024 Q1 2024 Q2 2024 DERMAdoctor Rx product expansion with DTC marketing efficiencies Co-Promotion Agreement Sale of DERMAdoctor for Co-Promotion activities addition of the Avenova contributed to decrease in to market Eyenovi
Slide 6: Building From a Highly Loyal Avenova Customer Base
Building From a Highly Loyal Avenova Customer Base AVENOVA SUBSCRIBERS ON AMAZON CURRENT "SUBSCRIBE AND SAVE" SUBSCRIPTIONS (Q1 & Q2 2024) 2500 2000 123% increase 1500 23% 31% 1000 500 Amazon Revenue Avenova.com 0 2022 2023 Jan-Jun '24 Revenue CUSTOMER RATINGS (as of June 2024) INCREASE IN SUBSCRIPT
Slide 7: Consistent Revenue From Eyecare Products
Consistent Revenue From Eyecare Products $3.0 $2.5 $2.4 $2.4* $2.3 $2.3 $2.2 $2.2 $2.0 $M $1.5 $1.0 $0.5 $- Q1' 23 Q2' 23 Q3' 23 Q4' 23 Q1' 24 Q2' 24 *Q2' 24 preliminary with estimated 2024 annual revenue of $10M Page 7
Slide 8: Avenova Lid & Lash Cleansing Spray
our hero product! Avenova Lid & Lash Cleansing Spray • Launched in 2015, Avenova was the first hypochlorous acid lid and lash cleansing spray on the market. • Hypochlorous acid has powerful antimicrobial properties with very low toxicity. • Commercial strategy is to extend product offerings to becom
Slide 9: Established Presence in Large, Growing U.S. Dry Eye Market
Established Presence in Large, Growing U.S. Dry Eye Market U.S. dry eye syndrome market is expected reach $4.86 billion by 20301 • 16 million Americans have confirmed dry eye syndrome • Dry eye syndrome is among the most observed clinical diseases in the U.S. Complex multifactorial disease that may
Slide 10: Avenova Efficacy Advantages
Avenova Efficacy Advantages • Inferior formulation can result in an ineffective solution and may contain harmful impurities such as bleach, plastic leachables and detergents • Bottled in amber glass to ensure the safest, purest, and most powerful HOCI lid & lash spray on the market Lab Test Results
Slide 11: Avenova Sales Channels - a doctor recommended brand
Avenova Sales Channels - a doctor recommended brand Rx - Retail Pharmacy Rx - Physician Dispensed OTC • Physicians prescribe Avenova • Physicians purchase Avenova • Physicians refer patients to Rx 40mL and patients fill Rx 20mL, at a discounted Avenova.com, Amazon, and prescriptions at a pharmacy pr
Slide 12: Avenova Opportunities for Growth
Avenova Opportunities for Growth Patients and Doctors can choose to purchase Avenova in the following ways: RX + RETAIL PHARMACY • Partnership with ImprimisRx, the nations largest ophthalmic compounding pharmacy • Rx version of Avenova available at 99% of retail pharmacies nationwide PHYSICIAN DISPE
Slide 13: Continued Growth in DTC Channel
Continued Growth in DTC Channel Vast majority of unit sales are currently through OTC channel Broad product accessibility through major online retailers Online “Subscribe & Save” feature on Avenova.com and Amazon.com, for repeat orders and revenue stabilization Core expertise in DTC digital marketin
Slide 14: Capitalizing on Physician Dispensed Channel
Capitalizing on Physician Dispensed Channel ESTABLISHED RELATIONSHIPS WITH THOUSANDS OF EYECARE SPECIALISTS OPENS NEW REVENUE OPPORTUNITIES • New affiliate programs provide network with access to special promotions aimed at increasing awareness of full suite of Avenova products • Marketing opportuni
Slide 15: Introducing Avenova Allograft
Introducing AVENOVA ALLOGRAFT FEATHER LIGHT, BUT POWERFUL New Differentiated, High-Quality Product Addressing Large Market Opportunity • The Avenova allograft is a dehydrated amniotic membrane utilized by eyecare professionals for the treatment of ocular surface diseases in the office setting • Lice
Slide 16: Co-Promotion Agreement for Synergistic Product
Co-Promotion Agreement for Synergistic Product • NovaBay to market Clobetasol Propionate Eyenovia, Inc. (NASDAQ: EYEN), Eyenovia, Inc. Ophthalmic Suspension 0.05% for the treatment is an ophthalmic technology company of post-operative inflammation and pain commercializing Mydcombi (tropicamide follo
Slide 17: Cap Table & Debt Overview
Cap Table & Debt Overview Capitalization (as of July 5, 2024) Common Stock Equivalents Common Stock 1,348,481 Warrants (WAEP $37.40) 224,777 Convertible Notes 119,495 Series B Convertible Preferred1 15,065 RSUs 5,148 Stock Options (WAEP $1,757.18) 1,756 Total Fully Diluted 1,714,722 1. Convertible a
Slide 18: Investment Highlights
Investment Highlights Predictable, Recurring Revenue Multipronged Growth Strategy Expense Management Estimated FY 2024 net revenue of Anticipated growth in both Purely commercial organization with $10M from eyecare products with one prescription and DTC channel. minimal R&D and clinical spend. quart
NovaBay Pharmaceuticals — Investor Presentation (July 2024) on 6ix